Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients
Contaminating tumor cells present in the BM or apheresis peripheral blood (APB) autologous transplant products have been shown to contribute to relapse following high-dose chemotherapy and stem-cell rescue (HDC/ASCR). Enhanced methods for tumor detection in BM or APB products for breast-cancer patie...
Gespeichert in:
| Veröffentlicht in: | Cytotherapy (Oxford, England) England), 1999-01, Vol.1 (5), p.367-376 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 376 |
|---|---|
| container_issue | 5 |
| container_start_page | 367 |
| container_title | Cytotherapy (Oxford, England) |
| container_volume | 1 |
| creator | Shammo, J.M. Smith, S.L. Bennett, M.V. Lee, H.W. Ostrander, A. Ross, A.A. Williams, S.F. |
| description | Contaminating tumor cells present in the BM or apheresis peripheral blood (APB) autologous transplant products have been shown to contribute to relapse following high-dose chemotherapy and stem-cell rescue (HDC/ASCR). Enhanced methods for tumor detection in BM or APB products for breast-cancer patients are required.
We evaluated a laboratory-scale tumor-cell enrichment column (TEC) as an enhanced method of detecting tumor cells in APB or BM of breast-cancer patients. Seventeen women with breast cancer (14 Stage IV and three Stage III) were evaluated using the TEC for residual tumor cells present in 20 samples of APB or BM biopsies following HDC/ASCR.
Using conventional histological staining methods (without TEC), only one patient had evidence of tumor cells present in the BM biopsy, while 16 patients had negative biopsies. Using the TEC for tumor cell capture and immunocytochemical (ICC) staining with anti-cytokeratin MAb (CAM 5.2) for tumor detection, we were able to positively identify tumor cells in 20 samples (14 BM aspirates and six APB products). In 15 samples (nine BM and six APB), we used CAM 5.2 to positively identify cytokeratin+ cells prior to using the TEC. However, positive cells were detected only after using the TEC in the remaining five samples. The level of sensitivity was significantly enhanced (p |
| doi_str_mv | 10.1080/0032472031000141282 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733124688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1465324999700435</els_id><sourcerecordid>19618159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-ad404b5d280e8b6799a94efa07bdf9a9d63b98237db8ae9156d9b70f3a3899b33</originalsourceid><addsrcrecordid>eNqFkctu1jAQhSMEoqXwBEjIK1gFfEtiL1hAxU0qYkPXkS8TxVViB9tB4rV4Qib8hRUqK4_l75yxzmmap4y-ZFTRV5QKLgdOBaOUMsm44veacyaHoeVd398_5r5rEdJnzaNSbijlVKnuYXPGqeR9J9R58_O6AEkTMaTua8qtg2UhEHNw8wqxEpeWfY1kSpnUGfBlNtGBJx4quBpSPMRriGE1C8lQgt9x8KGAQeMQf6vefiaoN9sMB1HIBjkcFyTtkpInNZtYtsXgwi0nv7taDl-b0aW27liZyWZqwC-Vx82DySwFntyeF831-3dfLz-2V18-fLp8c9U6KVltjZdU2s5zRUHZftDaaAmToYP1E86-F1YrLgZvlQHNut5rO9BJGKG0tkJcNC9OvvilbzuUOq6hHPmYCGkv4yAE47JXCsnnd5JM90yxTiMoTqDLqZQM07hlTC7_GBkdj1LHf5SKqme39rtdwf_V_GkRgdcnIEQsajUzmKXOzmQYb9KeI6b0nwW3esA4vwfIY3EYNfYcMrY8-hTu1P8CT9zFrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19618159</pqid></control><display><type>article</type><title>Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Alma/SFX Local Collection</source><creator>Shammo, J.M. ; Smith, S.L. ; Bennett, M.V. ; Lee, H.W. ; Ostrander, A. ; Ross, A.A. ; Williams, S.F.</creator><creatorcontrib>Shammo, J.M. ; Smith, S.L. ; Bennett, M.V. ; Lee, H.W. ; Ostrander, A. ; Ross, A.A. ; Williams, S.F.</creatorcontrib><description>Contaminating tumor cells present in the BM or apheresis peripheral blood (APB) autologous transplant products have been shown to contribute to relapse following high-dose chemotherapy and stem-cell rescue (HDC/ASCR). Enhanced methods for tumor detection in BM or APB products for breast-cancer patients are required.
We evaluated a laboratory-scale tumor-cell enrichment column (TEC) as an enhanced method of detecting tumor cells in APB or BM of breast-cancer patients. Seventeen women with breast cancer (14 Stage IV and three Stage III) were evaluated using the TEC for residual tumor cells present in 20 samples of APB or BM biopsies following HDC/ASCR.
Using conventional histological staining methods (without TEC), only one patient had evidence of tumor cells present in the BM biopsy, while 16 patients had negative biopsies. Using the TEC for tumor cell capture and immunocytochemical (ICC) staining with anti-cytokeratin MAb (CAM 5.2) for tumor detection, we were able to positively identify tumor cells in 20 samples (14 BM aspirates and six APB products). In 15 samples (nine BM and six APB), we used CAM 5.2 to positively identify cytokeratin+ cells prior to using the TEC. However, positive cells were detected only after using the TEC in the remaining five samples. The level of sensitivity was significantly enhanced (p<0.05) by 100–400 fold in the post-TEC (absorbed) fraction compared with the pre-TEC (post-Ficoll) fraction.
We conclude from this study that the use of TEC improves our ability to detect residual breast-cancer cells in the APB or BM and could be potentially utilized to purge contaminating tumor cells from the stem-cell transplant.</description><identifier>ISSN: 1465-3249</identifier><identifier>EISSN: 1477-2566</identifier><identifier>DOI: 10.1080/0032472031000141282</identifier><identifier>PMID: 20426538</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Adult ; Biopsy ; Blood Component Removal ; Blood Transfusion - methods ; Bone Marrow Transplantation - methods ; breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - immunology ; Breast Neoplasms - therapy ; Cell Transplantation - methods ; Combined Modality Therapy - methods ; Female ; Flow Cytometry - methods ; Humans ; Immunohistochemistry - methods ; Middle Aged ; minimal ; Neoplasm, Residual - blood ; Neoplasms - immunology ; Neoplasms - pathology ; Stem Cells - cytology ; tumor detection ; tumor enrichment</subject><ispartof>Cytotherapy (Oxford, England), 1999-01, Vol.1 (5), p.367-376</ispartof><rights>1999 International Society for Cellular Therapy</rights><rights>1999 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-ad404b5d280e8b6799a94efa07bdf9a9d63b98237db8ae9156d9b70f3a3899b33</citedby><cites>FETCH-LOGICAL-c441t-ad404b5d280e8b6799a94efa07bdf9a9d63b98237db8ae9156d9b70f3a3899b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/0032472031000141282$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/0032472031000141282$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,777,781,4010,27904,27905,27906,61200,61381</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20426538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shammo, J.M.</creatorcontrib><creatorcontrib>Smith, S.L.</creatorcontrib><creatorcontrib>Bennett, M.V.</creatorcontrib><creatorcontrib>Lee, H.W.</creatorcontrib><creatorcontrib>Ostrander, A.</creatorcontrib><creatorcontrib>Ross, A.A.</creatorcontrib><creatorcontrib>Williams, S.F.</creatorcontrib><title>Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients</title><title>Cytotherapy (Oxford, England)</title><addtitle>Cytotherapy</addtitle><description>Contaminating tumor cells present in the BM or apheresis peripheral blood (APB) autologous transplant products have been shown to contribute to relapse following high-dose chemotherapy and stem-cell rescue (HDC/ASCR). Enhanced methods for tumor detection in BM or APB products for breast-cancer patients are required.
We evaluated a laboratory-scale tumor-cell enrichment column (TEC) as an enhanced method of detecting tumor cells in APB or BM of breast-cancer patients. Seventeen women with breast cancer (14 Stage IV and three Stage III) were evaluated using the TEC for residual tumor cells present in 20 samples of APB or BM biopsies following HDC/ASCR.
Using conventional histological staining methods (without TEC), only one patient had evidence of tumor cells present in the BM biopsy, while 16 patients had negative biopsies. Using the TEC for tumor cell capture and immunocytochemical (ICC) staining with anti-cytokeratin MAb (CAM 5.2) for tumor detection, we were able to positively identify tumor cells in 20 samples (14 BM aspirates and six APB products). In 15 samples (nine BM and six APB), we used CAM 5.2 to positively identify cytokeratin+ cells prior to using the TEC. However, positive cells were detected only after using the TEC in the remaining five samples. The level of sensitivity was significantly enhanced (p<0.05) by 100–400 fold in the post-TEC (absorbed) fraction compared with the pre-TEC (post-Ficoll) fraction.
We conclude from this study that the use of TEC improves our ability to detect residual breast-cancer cells in the APB or BM and could be potentially utilized to purge contaminating tumor cells from the stem-cell transplant.</description><subject>Adult</subject><subject>Biopsy</subject><subject>Blood Component Removal</subject><subject>Blood Transfusion - methods</subject><subject>Bone Marrow Transplantation - methods</subject><subject>breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cell Transplantation - methods</subject><subject>Combined Modality Therapy - methods</subject><subject>Female</subject><subject>Flow Cytometry - methods</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Middle Aged</subject><subject>minimal</subject><subject>Neoplasm, Residual - blood</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Stem Cells - cytology</subject><subject>tumor detection</subject><subject>tumor enrichment</subject><issn>1465-3249</issn><issn>1477-2566</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1jAQhSMEoqXwBEjIK1gFfEtiL1hAxU0qYkPXkS8TxVViB9tB4rV4Qib8hRUqK4_l75yxzmmap4y-ZFTRV5QKLgdOBaOUMsm44veacyaHoeVd398_5r5rEdJnzaNSbijlVKnuYXPGqeR9J9R58_O6AEkTMaTua8qtg2UhEHNw8wqxEpeWfY1kSpnUGfBlNtGBJx4quBpSPMRriGE1C8lQgt9x8KGAQeMQf6vefiaoN9sMB1HIBjkcFyTtkpInNZtYtsXgwi0nv7taDl-b0aW27liZyWZqwC-Vx82DySwFntyeF831-3dfLz-2V18-fLp8c9U6KVltjZdU2s5zRUHZftDaaAmToYP1E86-F1YrLgZvlQHNut5rO9BJGKG0tkJcNC9OvvilbzuUOq6hHPmYCGkv4yAE47JXCsnnd5JM90yxTiMoTqDLqZQM07hlTC7_GBkdj1LHf5SKqme39rtdwf_V_GkRgdcnIEQsajUzmKXOzmQYb9KeI6b0nwW3esA4vwfIY3EYNfYcMrY8-hTu1P8CT9zFrw</recordid><startdate>199901</startdate><enddate>199901</enddate><creator>Shammo, J.M.</creator><creator>Smith, S.L.</creator><creator>Bennett, M.V.</creator><creator>Lee, H.W.</creator><creator>Ostrander, A.</creator><creator>Ross, A.A.</creator><creator>Williams, S.F.</creator><general>Elsevier Inc</general><general>Informa UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>199901</creationdate><title>Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients</title><author>Shammo, J.M. ; Smith, S.L. ; Bennett, M.V. ; Lee, H.W. ; Ostrander, A. ; Ross, A.A. ; Williams, S.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-ad404b5d280e8b6799a94efa07bdf9a9d63b98237db8ae9156d9b70f3a3899b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Biopsy</topic><topic>Blood Component Removal</topic><topic>Blood Transfusion - methods</topic><topic>Bone Marrow Transplantation - methods</topic><topic>breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cell Transplantation - methods</topic><topic>Combined Modality Therapy - methods</topic><topic>Female</topic><topic>Flow Cytometry - methods</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Middle Aged</topic><topic>minimal</topic><topic>Neoplasm, Residual - blood</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Stem Cells - cytology</topic><topic>tumor detection</topic><topic>tumor enrichment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shammo, J.M.</creatorcontrib><creatorcontrib>Smith, S.L.</creatorcontrib><creatorcontrib>Bennett, M.V.</creatorcontrib><creatorcontrib>Lee, H.W.</creatorcontrib><creatorcontrib>Ostrander, A.</creatorcontrib><creatorcontrib>Ross, A.A.</creatorcontrib><creatorcontrib>Williams, S.F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cytotherapy (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shammo, J.M.</au><au>Smith, S.L.</au><au>Bennett, M.V.</au><au>Lee, H.W.</au><au>Ostrander, A.</au><au>Ross, A.A.</au><au>Williams, S.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients</atitle><jtitle>Cytotherapy (Oxford, England)</jtitle><addtitle>Cytotherapy</addtitle><date>1999-01</date><risdate>1999</risdate><volume>1</volume><issue>5</issue><spage>367</spage><epage>376</epage><pages>367-376</pages><issn>1465-3249</issn><eissn>1477-2566</eissn><abstract>Contaminating tumor cells present in the BM or apheresis peripheral blood (APB) autologous transplant products have been shown to contribute to relapse following high-dose chemotherapy and stem-cell rescue (HDC/ASCR). Enhanced methods for tumor detection in BM or APB products for breast-cancer patients are required.
We evaluated a laboratory-scale tumor-cell enrichment column (TEC) as an enhanced method of detecting tumor cells in APB or BM of breast-cancer patients. Seventeen women with breast cancer (14 Stage IV and three Stage III) were evaluated using the TEC for residual tumor cells present in 20 samples of APB or BM biopsies following HDC/ASCR.
Using conventional histological staining methods (without TEC), only one patient had evidence of tumor cells present in the BM biopsy, while 16 patients had negative biopsies. Using the TEC for tumor cell capture and immunocytochemical (ICC) staining with anti-cytokeratin MAb (CAM 5.2) for tumor detection, we were able to positively identify tumor cells in 20 samples (14 BM aspirates and six APB products). In 15 samples (nine BM and six APB), we used CAM 5.2 to positively identify cytokeratin+ cells prior to using the TEC. However, positive cells were detected only after using the TEC in the remaining five samples. The level of sensitivity was significantly enhanced (p<0.05) by 100–400 fold in the post-TEC (absorbed) fraction compared with the pre-TEC (post-Ficoll) fraction.
We conclude from this study that the use of TEC improves our ability to detect residual breast-cancer cells in the APB or BM and could be potentially utilized to purge contaminating tumor cells from the stem-cell transplant.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>20426538</pmid><doi>10.1080/0032472031000141282</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-3249 |
| ispartof | Cytotherapy (Oxford, England), 1999-01, Vol.1 (5), p.367-376 |
| issn | 1465-3249 1477-2566 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733124688 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Alma/SFX Local Collection |
| subjects | Adult Biopsy Blood Component Removal Blood Transfusion - methods Bone Marrow Transplantation - methods breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - immunology Breast Neoplasms - therapy Cell Transplantation - methods Combined Modality Therapy - methods Female Flow Cytometry - methods Humans Immunohistochemistry - methods Middle Aged minimal Neoplasm, Residual - blood Neoplasms - immunology Neoplasms - pathology Stem Cells - cytology tumor detection tumor enrichment |
| title | Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A03%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20a%20tumor-cell%20enrichment%20column%20for%20the%20enhanced%20detection%20of%20minimal%20residual%20disease%20in%20the%20BM%20or%20apheresis%20peripheral%20blood%20transplant%20products%20of%20breast-cancer%20patients&rft.jtitle=Cytotherapy%20(Oxford,%20England)&rft.au=Shammo,%20J.M.&rft.date=1999-01&rft.volume=1&rft.issue=5&rft.spage=367&rft.epage=376&rft.pages=367-376&rft.issn=1465-3249&rft.eissn=1477-2566&rft_id=info:doi/10.1080/0032472031000141282&rft_dat=%3Cproquest_cross%3E19618159%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19618159&rft_id=info:pmid/20426538&rft_els_id=S1465324999700435&rfr_iscdi=true |